At the first-ever CG Well Summit, hosted by Canaccord Genuity Group, the new brain health and wellness company BEVIMI officially launched. The event brought together
Real-world evidence demonstrates PurIST’s ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma Tempus AI, a technology company
Tempus’ generative AI-enabled clinical assistant is designed to support providers in unlocking new insights and efficiencies Northwestern Medicine and Tempus AI, Inc. announced a notable
Tempus has expanded its AI-based Care Pathway Intelligence platform to cover breast cancer, following its acquisition of experience in lung, pancreatic, and ovarian cancers. The
Tempus AI, a technology company leading the adoption of AI to advance precision medicine and patient care, announced a collaboration with The Abrams Research Center
Tempus AI, a technology company leading the adoption of AI to advance precision medicine and patient care, announced xM for treatment response monitoring (TRM), a
The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling Tempus AI, a technology company
Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, announced a new strategic collaboration to advance
Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an
Tempus AI, Inc , a technology company leading the adoption of AI to advance precision medicine and patient care, announced the launch of the Tempus
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease Illumina Inc. and Tempus AI, Inc. a technology company leading
Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for
